Differential metabolite results, listing metabolites with significant changes across treatment groups, including fold changes, and <i>p</i>-values.

Differential metabolite results, listing metabolites with significant changes across treatment groups, including fold changes, and <i>p</i>-values.

<p>Differential metabolite results, listing metabolites with significant changes across treatment groups, including fold changes, and <i>p</i>-values.</p>

Guardado en:

Detalles Bibliográficos
Autor principal:	Ji-Xin Zhao (22056386) (author)
Otros Autores:	Wen-Bin Zheng (3328680) (author), Shi-Chen Xie (10678094) (author), He Ma (583317) (author), Xiao-Tong Chen (4217488) (author), Ying-Qian Gao (22683622) (author), Lu-Yao Tang (22683625) (author), Meng-Ting Yang (10714266) (author), Fu-Long Nan (22056395) (author), Jing Jiang (130103) (author), Hany M. Elsheikha (6910232) (author), Xiao-Xuan Zhang (610969) (author)
Publicado:	2025
Materias:	Biochemistry Microbiology Cell Biology Genetics Physiology Ecology Immunology Computational Biology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified showed negative associations quality reads produced oxidative stress response conducted metagenomic sequencing compositional changes coincided bile acid transformation aromatic compound processing 7 million genes rothia nasimurium </ lactobacillus intestinalis </ de novo </ untargeted serum metabolomics specific metabolic disruptions amino acid metabolism toxoplasma gondii </ limosilactobacillus reuteri </ lactobacillus johnsonii </ akkermansia muciniphila </ host systemic metabolism disrupts intestinal microbiota reuteri </ muciniphila </ johnsonii </ gondii </ host metabolism untargeted lc metabolic targets energy metabolism infection disrupts significant shifts reduced abundance rat model positively correlated pathways related novel microbial microbial diversity metabolites implicated marked reduction marked depletion key role immune modulation gut microbiota findings demonstrate enhanced glycan disease mechanisms comprehensive non community structure chronic stages active enzymes 18 sprague
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

KEGG pathway enrichment analysis of differential serum metabolites.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Spearman correlation analysis between gut microbial taxa and circulating metabolites, detailing correlation coefficients, significance values, and taxon–metabolite pairings indicative of microbiome–host metabolic interactions.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Correlation network between intestinal bacterial species and differential serum metabolites.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Pathway enrichment analysis of differential metabolites, highlighting significantly impacted metabolic pathways and associated enrichment statistics based on KEGG or other pathway databases.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Effects of <i>T. gondii</i> infection on rat gut microbiota diversity.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Untargeted serum metabolomics analysis before and after <i>T. gondii</i> infection.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Functional analysis of the intestinal microbial community following <i>T. gondii</i> infection.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Composition of intestinal microbial communities in the large intestine of rats before and after <i>T. gondii</i> infection.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Composition of intestinal microbial communities in the small intestine of rats before and after <i>T. gondii</i> infection.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Orthogonal partial least squares-discriminant analysis (OPLS-DA) of serum metabolomics data.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Quality control assessment of serum metabolomics data.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Heatmap of enriched KEGG pathways across samples, illustrating variations in pathway abundance.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Graphical abstract.
por: Ji-Xin Zhao (22056386)
Publicado: (2025)

Image 3_Palmitic acid differently modulates extracellular vesicles and cellular fatty acid composition of SGBS adipocytes without impairing their insulin signaling.png
por: Domenico Sergi (435399)
Publicado: (2025)

Image 1_Palmitic acid differently modulates extracellular vesicles and cellular fatty acid composition of SGBS adipocytes without impairing their insulin signaling.jpeg
por: Domenico Sergi (435399)
Publicado: (2025)

Image 2_Palmitic acid differently modulates extracellular vesicles and cellular fatty acid composition of SGBS adipocytes without impairing their insulin signaling.jpeg
por: Domenico Sergi (435399)
Publicado: (2025)

Image 1_Oral health indices and microbiota populations of adult cats consuming wet or dry diets.tiff
por: Patrícia M. Oba (13186074)
Publicado: (2025)

Protocatechuic Acid alleviates D-gal-induced renal senescence and injury in mice by regulating taurine metabolism
por: Songhao Tian (22609826)
Publicado: (2025)

Supplementary file 2_Clinical efficacy and metabolomics profiling of dachaihu decoction for patients with septic liver injury: a randomized controlled trial.doc
por: Zhen Yang (107412)
Publicado: (2025)

Supplementary file 1_Clinical efficacy and metabolomics profiling of dachaihu decoction for patients with septic liver injury: a randomized controlled trial.pdf
por: Zhen Yang (107412)
Publicado: (2025)

Supplementary file 4_Clinical efficacy and metabolomics profiling of dachaihu decoction for patients with septic liver injury: a randomized controlled trial.docx
por: Zhen Yang (107412)
Publicado: (2025)

Supplementary file 3_Clinical efficacy and metabolomics profiling of dachaihu decoction for patients with septic liver injury: a randomized controlled trial.docx
por: Zhen Yang (107412)
Publicado: (2025)

A. <i>T. gondii</i> gene group changes throughout the time course, expressed as log<sub>2</sub>(fold change) relative to pre-infection tachyzoites (t = 0). Grey area depicts the 95% confidence interval. n value refers to number of genes detected in each group. B. Gene set enrichment plot for most enriched terms from <i>T. gondii</i> transcriptome features at 15 min to 120 min. Five most significant terms are displayed for each database. C and D. Transcriptional profiles of top five upregulated and downregulated <i>T. gondii</i> transcription factors, respectively.
por: Dominykas Murza (22676289)
Publicado: (2025)

Table 1_Association between vascular aging and cardiovascular-kidney-metabolic syndrome.docx
por: Shuyi Zeng (8551422)
Publicado: (2025)

Table 1_GLP-1 agonists and exercise: the future of lifestyle prioritization.docx
por: Roberto Codella (5856173)
Publicado: (2025)

羟丙基甲基纤维素通过对抗杆菌类驱动的CDCA富集，逆转结肠炎中菊糖的促炎作用
por: 宇郑 (22678961)
Publicado: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
por: Snehanshu Chowdhury (14957031)
Publicado: (2025)

Quantitative Proteomics Links Mitochondrial Dysfunction to Metabolic Changes and Epithelial Differentiation Defects in Hyperoxia-Exposed Neonatal Airway Cells
por: Abhrajit Ganguly (21540245)
Publicado: (2025)

A. Library preparation strategy: poly-A(+) RNAs are captured by complementarity to reverse transcription primer, then second strand is synthesized using random hexamers and handles for sequencing are attached through two rounds of PCR. B. Mapped read distribution by species and by biotype. C and D. Principal component analysis of mouse and <i>T. gondii</i> transcriptomes, respectively. E and F. Volcano plots of Live <i>Toxoplasma</i>-infected mouse and <i>T. gondii</i> time points, respectively. To calculate Log<sub>2</sub>(Fold change), every timepoint is compared to corresponding samples (either macrophage or <i>Toxoplasma</i>) before infection (t = 0 min). Most significant and most upregulated transcripts are labelled. Number of significantly (p ≤ 0.05) downregulated and upregulated genes for each time point is given in blue and red, respectively. In F, 24-hour time point, red dots mark ROP
por: Dominykas Murza (22676289)
Publicado: (2025)

Supplementary Table S1 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
por: Gia-Buu Tran (16437051)
Publicado: (2025)

Supplementary Table S2 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
por: Gia-Buu Tran (16437051)
Publicado: (2025)

Table S3 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
por: Gia-Buu Tran (16437051)
Publicado: (2025)

Table S4 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
por: Gia-Buu Tran (16437051)
Publicado: (2025)

Table S5 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
por: Gia-Buu Tran (16437051)
Publicado: (2025)

Supplementary Table S2 from Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells
por: Pochung Jordan Chou (14851578)
Publicado: (2025)

Supplementary Table S3 from Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells
por: Pochung Jordan Chou (14851578)
Publicado: (2025)

Supplementary Table S4 from Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells
por: Pochung Jordan Chou (14851578)
Publicado: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
por: David Olayinka Kamson (16617218)
Publicado: (2025)

Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
por: David Olayinka Kamson (16617218)
Publicado: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
por: William Kelly (15439117)
Publicado: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3qp19bpcsrejgcekh12ie35amf